Clinical Trial Update: A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating SHR-A1811 in HER2-expressing recurrent or metastatic cervical cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• SHR-A1811

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Recurrent or Metastatic Cervical Cancer | Phase 2 | Status: RECRUITING